- Home
- CDE vs PTGX Comparison
CDE vs PTGX Comparison
Compare CDE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- PTGX
- Stock Information
- Founded
- CDE 1928
- PTGX 2006
- Country
- CDE United States
- PTGX United States
- Employees
- CDE N/A
- PTGX N/A
- Industry
- CDE Precious Metals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CDE Basic Materials
- PTGX Health Care
- Exchange
- CDE Nasdaq
- PTGX Nasdaq
- Market Cap
- CDE 2.4B
- PTGX 2.8B
- IPO Year
- CDE N/A
- PTGX 2016
- Fundamental
- Price
- CDE $7.84
- PTGX $42.97
- Analyst Decision
- CDE Strong Buy
- PTGX Strong Buy
- Analyst Count
- CDE 4
- PTGX 8
- Target Price
- CDE $8.00
- PTGX $66.50
- AVG Volume (30 Days)
- CDE 16.6M
- PTGX 990.2K
- Earning Date
- CDE 05-07-2025
- PTGX 05-06-2025
- Dividend Yield
- CDE N/A
- PTGX N/A
- EPS Growth
- CDE N/A
- PTGX N/A
- EPS
- CDE 0.27
- PTGX 0.86
- Revenue
- CDE $1,201,008,000.00
- PTGX $207,801,000.00
- Revenue This Year
- CDE $53.22
- PTGX N/A
- Revenue Next Year
- CDE $7.37
- PTGX $7.13
- P/E Ratio
- CDE $28.58
- PTGX $50.68
- Revenue Growth
- CDE 41.80
- PTGX N/A
- 52 Week Low
- CDE $4.57
- PTGX $24.22
- 52 Week High
- CDE $7.72
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- CDE 75.04
- PTGX 43.08
- Support Level
- CDE $5.21
- PTGX $41.29
- Resistance Level
- CDE $5.51
- PTGX $46.12
- Average True Range (ATR)
- CDE 0.35
- PTGX 1.83
- MACD
- CDE 0.19
- PTGX -0.19
- Stochastic Oscillator
- CDE 99.43
- PTGX 27.81
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.